Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 5, 2007, Pages 481-486

  Kim, Chan Yun ^a   Hong, Samin ^a   Seong, Gong Je ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; BRIMUNIDINE PURITE; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EYELID EDEMA; FATIGUE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESSURE MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CONJUNCTIVITIS, ALLERGIC; CROSS-OVER STUDIES; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PIGMENT EPITHELIUM OF EYE; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; QUINOXALINES; SINGLE-BLIND METHOD; THERAPEUTIC EQUIVALENCY;

EID: 36749034325     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0042     Document Type: Article

References (23)

1. Melanmed, A., and David, R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol; Year-three results. Clin. Ther. 22:103-111, 2000.
2. Walters, T.R. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies. Surv. Ophthalmol. 41(Suppl. 1):S19-S26, 1996.
3. Toris, C.B., Gleaseon, M.L., Camras, C.B., et al. Effects brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 113:1513-1517, 1995.
4. Schuman, J.S., Horwitz, B., Choplin, N.T., et al. A 1-year study of brimonidine twice-daily in glaucoma and ocular hypertension: A controlled, randomized, multicenter clinical trial. The Chronic Brimonidine Study Group. Arch. Ophthalmol. 115:847-852, 1997.
5. Lee, D.A. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clin. Ther. 22:53-65, 2000.
6. Lee, D.A., Gornbein, J., and Abrams, C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: A post hoc analysis of an open-label community trial. The Glaucoma Trial Study Group. J. Ocul. Pharmacol. Ther. 16:3-18, 2000.
7. Chen, T.C., Ang, R.T., Grosskreuz, C.L., et al. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery. Ophthalmology 108:1033-1038, 2001.
8. Seong, G.J., Lee, Y.G., Lee, J.H., et al. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy. Ophthalmic Surg. Lasers 31:308-314, 2000.
9. Schuman, J.S. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv. Ophthalmol. 41(Suppl. 1):S27-S37, 1996.
10. Katz, L.J. Brimonidine tartrate 0.2% twice-daily vs. timolol 0.5% twice-daily: 1-year results in glaucoma patients. The Brimonidine Study Group. Am. J. Ophthalmol. 127:20-26, 1999.
11. Serle, J.B. A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv. Ophthalmol. 41:S39-S47, 1996.
12. Masschelein, W.J. Chlorine Dioxide: Chemistry and Environmental Impact of Oxychlorine Compounds. Ann Arbor, MI: Ann Arbor Science, 1979.
13. Grant, R., Ajello, M., and Vlass, E. Salt water or high tech? A look at two new rinsing solutions for contact lenses. Optician 212:38-41, 1996.
14. Katz, L.J. Twelve-month evaluation of brimonidinepurite versus brimonidine in patiens with glaucoma or ocular hypertension. J. Glaucoma 11:119-126, 2002.
15. Mundorf, T., Williams, R., Whitcup, S., et al. 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 19:37-44, 2003.
16. Acheampong, A.A., Shackleton, M., and Tang-Liu, D.D. Comparative ocular pharmacokinetics of brimonidine after a single-dose application to the eyes of albino and pigmented rabbits. Drug Metab. Dispos. 23:708-712, 1995.
17. Acheampong, A.A., Shackleton, M., John, B., et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30:421-429, 2002.
18. LeBlanc, R.P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice-daily in glaucoma or ocular hypertension. The Brimonidine Study Group 2. Ophthalmology 105:1960-1967, 1998.
19. Gilman, A.G., Goodman, L.S., Rall, T.W., et al. The Pharmacological Basis of Therapeutics. New York: Macmillan, 1985:33.
20. Stewart, W.C., Sharpe, E.D., Harbin, T.S. Jr., et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am. J. Ophthalmol. 129:723-727, 2000.
21. Bondeau, P., and Rousseau, J.A. Allergic reactions to brimonidine in patients treated for glaucoma. Can. J. Ophthalmol. 37:21-26, 2002.
22. Butler, P., Mannschreck, M., Lin, S., et al. Clinical experience with the long-term use of 1% apraclonidine. Arch. Ophthalmol. 113;293-296, 1995.
23. Konstas, A.G., Stewart, W.C., Topouzis, F., et al. Brimonidine 0.2% given two- or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol. 131:729-733, 2001.